Nipun Davar

Nipun Davar, Ph.D., joined Threshold as Vice President of Pharmaceutical Development and Manufacturing in October 2011. Dr. Davar has more than 17 years of product development experience in the pharmaceutical industry. Prior to Threshold, Dr. Davar was Vice President of Pharmaceutical Sciences at Transcept Pharmaceuticals where he led the CMC function and pharmaceutical development of Intermezzo® (low dose sublingual zolpidem) for the treatment of middle of the night insomnia. Prior to Transcept, Dr. Davar held various leadership positions at ALZA, most recently as Senior Director and Research Fellow, where he led multidisciplinary teams responsible for the approval of Jurnista® (OROS hydromorphone) in Europe and Invega® (OROS paliperidone) in the U.S. He has 11 issued or pending patent applications and multiple publications in the area of drug delivery and product development. Dr. Davar holds a Ph.D. in Pharmaceutical Sciences from the University of Maryland and an MBA from the Wharton School at the University of Pennsylvania.